Affimed to Present Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH
08 November 2016 - 9:00PM
Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical
company focused on discovering and developing highly targeted
cancer immunotherapies, today announced that three of the Company’s
abstracts have been chosen for poster presentations at the 58th
American Society of Hematology (ASH) Annual Meeting and Exposition,
being held December 3-6, 2016 in San Diego, California.
Poster Information
AFM13 Is the Most Advanced Bispecific NK-Cell Engaging
Antibody in Clinical Development Substantially Enhancing NK-Cell
Effector Function and Proliferation (Abstract #1764) |
Session: 622. Lymphoma Biology - Non-Genetic Studies: Poster I |
Date: Saturday, December 3, 2016: 5:30-7:30 p.m.
(PT) |
Location: Hall GH (San Diego Convention Center) |
|
Functional Defects of T Cells of NHL Patients after
Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent
Bispecific TandAb® AFM11
(Abstract #4130) |
Session: 622. Lymphoma
Biology - Non-Genetic Studies: Poster III |
Date: Monday,
December 5, 2016: 6:00-8:00 p.m. Pacific Time |
Location: Hall GH (San Diego Convention Center) |
|
Trispecific Antibodies for Selective CD16A-Directed NK-Cell
Engagement in Multiple Myeloma (Abstract #4513) |
Session: 653. Myeloma: Therapy, excluding
Transplantation: Poster III |
Date: Monday, December 5, 2016: 6:00-8:00 p.m. Pacific
Time |
Location: Hall GH (San Diego Convention Center) |
About AFM13
AFM13 is a bispecific NK-cell TandAb
simultaneously targeting CD16A on NK-cells and CD30 on tumor cells.
AFM13 is designed to treat CD30-positive malignancies including
Hodgkin lymphoma (HL) and T-cell lymphoma (TCL) and is currently in
Phase 2 studies in HL patients. Based on its appropriate safety
profile, AFM13 is being developed both as monotherapy and in
combination with other therapeutics such as our collaboration
partner Merck’s checkpoint inhibitor KEYTRUDA®.
About AFM11
AFM11 is a bispecific T-cell TandAb
simultaneously targeting CD3 on T-cells and CD19 on tumor cells.
AFM11 is specifically designed to treat B-cell malignancies
including non-Hodgkin lymphoma (NHL) and acute lymphoblastic
leukemia (ALL), in which CD19 is expressed at abnormally high
levels. AFM11 is currently in Phase 1 clinical development for NHL
and ALL.
About NK- and T-Cell TandAbs and
Trispecific Antibodies
TandAbs and Trispecific Abs are immune
cell-engaging antibodies with a tetravalent architecture
characterized by four binding domains. Affimed develops products
from three proprietary platforms:
- Bispecific TandAbs engaging NK-cells (via CD16A)
- Bispecific TandAbs engaging T-cells (via CD3)
- Trispecific Abs engaging either NK- or T-cells
Affimed develops TandAbs and Trispecific Abs to
substantially increase the efficacy, specificity and/or extend the
therapeutic window of current therapeutics. Binding to targets on
both the immune and the tumor cell, they redirect immune cells and
establish a bridge between either NK-cells or T-cells and cancer
cells, triggering a signal cascade that leads to the destruction of
cancer cells. In clinical studies, our TandAb products have already
demonstrated promising signs of therapeutic activity in
patients.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK- and T-cells). We are
developing single and combination therapies to treat cancers and
other life-threatening diseases. For more information, please visit
www.affimed.com.
IR Contact:
Caroline Stewart, Head IRPhone: +1 347394 6793E-Mail:
IR@affimed.com or c.stewart@affimed.com
Media Contact:
Anca Alexandru, Head of Communications, EU IRPhone: +49 6221
64793341E-Mail: a.alexandru@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2024 to May 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From May 2023 to May 2024